Evaluation of the Efficacy and Safety of Silodosin in the Treatment of the Signs and Symptoms of BPH
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
A new drug for the treatment of benign prostatic hyperplasia is compared with placebo and
tamsulosin (a drug belonging to the same therapeutic class) for to determine if it is safe
and effective (the first phase of the study lasts approximately 18 weeks) and then is used
for another 9 months to determine its long-term safety.
Phase:
Phase 3
Details
Lead Sponsor:
RECORDATI GROUP Recordati Industria Chimica e Farmaceutica S.p.A.